Share
Cell-Based Cancer Immunotherapy (Volume 183) (Methods in Cell Biology, Volume 183)
Garg Abhishek,Galluzzi Lorenzo (Author)
·
Academic Press
· Nuevo
Cell-Based Cancer Immunotherapy (Volume 183) (Methods in Cell Biology, Volume 183) - Garg Abhishek,Galluzzi Lorenzo
£ 125.10
£ 139.00
You save: £ 13.90
Choose the list to add your product or create one New List
✓ Product added successfully to the Wishlist.
Go to My WishlistsIt will be shipped from our warehouse between
Tuesday, July 23 and
Monday, August 12.
You will receive it anywhere in United Kingdom between 1 and 3 business days after shipment.
Synopsis "Cell-Based Cancer Immunotherapy (Volume 183) (Methods in Cell Biology, Volume 183)"
Cell-based Cancer Immunotherapy, Volume 183 provides the latest progress concerning research on anticancer cellular immunotherapies and their immunological, translation, or clinical aspects. Topics covered in this volume include Methods behind clinical DC vaccine products against glioblastoma, Fully closed and automated isolation of natural blood dendritic cells for cancer immunotherapy, Methods behind Oncolytic virus-based DC vaccines in cancer: towards a multiphase combined treatment strategy for Glioblastoma (GBM) patients, Identification of TCR repertoire patterns linked with anti-cancer immunotherapy, Training of epitope-TCR prediction models with healthy donor-derived cancer-specific T cells, Methods behind neoantigen predictions for anticancer vaccines, Methods behind CD137L-DC-EBV-VAX anticancer vaccine, and much more. Additional sections cover Gold Standard Assessment of Immunogenic Cell Death Induced by Photodynamic Therapy: From In Vitro to Tumor Mouse Models and Anti-Cancer Vaccination Strategies, Methods behind TCR analyses for colorectal cancer-associated TILs, The use of xCELLigence, Incucyte, and/or Cr/LDH/maker-release assays, Humanized mouse models for anti-cancer therapy, In vitro re-challenge of CAR T cells, Methods behind adoptively transferred tumor draining lymphocytes? for anticancer immunotherapy, and A murine glioblastoma platform to test cellular therapies with the standard of care.
